Immunohistochemical phospho tensin tumor suppressor gene staining patterns in endometrial hyperplasias: A 2-year study

Indian Journal of Pathology and Microbiology

Volumn 54, Issue 2, 2011, Pages 264-268

  Rao, Anuradha C K ^a   Arya, Garima ^b   Padma, Priya J ^a  

^a KASTURBA MEDICAL COLLEGE   (India)

^b NONE

Author keywords

Endometrial carcinoma; hyperplasia; phospho tensin tumor suppressor gene expression

Indexed keywords

ADULT; ARTICLE; CANCER RISK; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PHOSPHO TENSIN GENE; TUMOR SUPPRESSOR GENE;

ADULT; BIOLOGICAL MARKERS; ENDOMETRIAL HYPERPLASIA; ENDOMETRIUM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PTEN PHOSPHOHYDROLASE; TUMOR SUPPRESSOR PROTEINS;

EID: 79959246829     PISSN: 03774929     EISSN: 09745130     Source Type: Journal    
DOI: 10.4103/0377-4929.81588     Document Type: Article

References (29)

1. Creaseman WT. Endometrial cancer: Incidence, prognostic factors, diagnosis and treatment. Semin Oncol 1997;24:1-140.
2. Mutter GL, Ince TA, Baak J P, Kust G, Zhen X, Eng C. Molecular identification of latent precancers in histologically normal endometrium. Cancer Res 200;6:4311-4.
3. th ed. Berlin: Springer - Verlag; 1987. p. 93-294.
4. Haines M, Taylor CW. The uterus. In: Haines M, editor. Gynaecological Pathology. Baston: Little, Brown and Company; 1962. p. 148-78.
5. Kendall BS, Ronnett BM, Isacson C, Cho KR, Hedrick L, West MD, et al. Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia and well - differentiated carcinoma. Am J Surg Pathol 1998;22:1012-9. (Pubitemid 28364502)
6. Kurman RJ, Kaminiski P F, Norris HJ. The behavior of endometrial hyperplasia. Cancer 1985;56:403-12.
7. Mutter GL. Diagnosis of premalignant endometrial disease. J Clin Pathol 2002;55:326-31. (Pubitemid 34494169)
8. th ed. New York: Sringer Verlag; 2002. p. 501-46.
9. Maxwell GL, Risinger JI, Gumbs C, Shaw H, Bentley RC, Barett C, et al. Mutation of the PTEN tumor suppresser Gene in Endometrial Hyperplasias. Cancer Res 1998;58:2500-3. (Pubitemid 28275414)
10. Sansal I, Sellars WR. The Biology and Clinical Relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004;22:2954-63. (Pubitemid 41079915)
11. Tamura M, Gu J, Tran H, Yamada KH. PTEN Gene and Integrin Signaling in Cancer. J Natl Cancer Inst 1999;91:1820-8.
12. Bilbao C, Rodriguez G, Ramirez R, Falcon O, Leon L, Chirino R, et al. The relationship between microsatellite instability and PTEN gene mutations in endometrial cancer. Int J Cancer 2006;119:563-70. (Pubitemid 43955709)
13. Wong L P, Brown JL, Eng C. PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and independent pathways. Hum Mol Genet 2001;10:237-42. (Pubitemid 32123982)
14. Guzeloqlu KO, Kayisli UA, Al RR, Zheng W, Luleci G, Arici A. Regulation of PTEN (Phosphatase and tensin homolog deleted on chromosome 10) expression by estradiol and progesterone in human endometrium. J Clin Endocrinol Metab 2003;88:5017-26. (Pubitemid 37357558)
15. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Eng C. Changes in Endometrial PTEN expression throughout the human menstrual cycle. J Clin Endocrinol Metab 2000;85:2334-8. (Pubitemid 32269265)
16. Baak JP, Diermen B V, Steinbakk A, Janssen E, Skaland I, Mutter GL, et al. Lack of PTEN expression in endometrial intraepithelial neoplasia is correlated with cancer progression. Hum Pathol 2005;36:555-61. (Pubitemid 40776009)
17. Mutter GL. PTEN, a protean Tumor Supressor. Am J Pathol 2001;158:1895-8.
18. Ali IU. Gatekeeper for endometrium: The PTEN Tumor Suppressor Gene. J Natl Cancer Inst 2000;92:861-3. (Pubitemid 30429187)
19. Hecht JL, Pinkus JL, Pinkus GS. Enhanced detection of Atypical Hyperplasia in Endometrial Polyps by PTEN expression. Appl Immunohistochem Mol Morphol 2004;12:1-8.
20. Pallares J, Bussaglia E, Guitare JL, Dolcet X, Llobet D, Rue M, et al. Immunohistochemical analysis of PTEN in endometrial carcinoma: A tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities. Mod Pathol 2005;18:719-27. (Pubitemid 40676385)
21. Mutter GL, Lin MC, Fitzgerald JT, Kun JB, Baak J P, Lees JA, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial pre cancers. J Natl Cancer Inst 2000;92:924-30.
22. Erkanli S, Kayaselcuk F, Kuscu E, Bagis T, Bolat F, Haberal A, et al. Expression of survivin, PTEN and p27 in normal, hyperplastic and carcinomatous endometrium. Int J Gynecol Cancer 2006;16:1412-8. (Pubitemid 43886778)
23. 1 endometroid adenocarcinoma of the uterine corpus. J Can Res Clin Oncol 2004;130:161-8. (Pubitemid 38392349)
24. Taranger-Charpin C, Carpentier C, Dales J P, Gracia S, Djemci A, Andrac L, et al. Immunohistochemical expression of PTEN antigen: A new tool for diagnosis of early endometrial neoplasia. Bull Acad Natl Med 2004;188:415-27.
25. Kanamori Y, Kingawa J, Itamochi H, Shimada M, Takahashi M, Kamazawa S, et al. Correlation between Loss of PTEN expression of Akt phosphorylation in Endometrial Carcinoma. Clin Cancer Res 2001;7:892-5. (Pubitemid 32708726)
26. Peiro G, Lohse P, Mayr D, Diebold J. Insulin like growth factor-1 Receptor and PTEN protein expression in endometrial carcinoma. Am J Clin Pathol 2003;120:78-85.
27. Inaba F, Kawamata H, Teramoto T, Fukasawa I, Inaba N, Fujimori T. PTEN and P53 abnormalities are indicative and predictive factors for endometrial carcinoma. Oncol Rep 2005;13:17-24.
28. Salvesen HB, Stefansson I, Kalvenes MB, Das S, Akslen LA. Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma. Cancer 2002;94:2185-91. (Pubitemid 34411976)
29. nd ed. China: Elsevier; 2006. p. 637-98.